Wassil Jim 4

What Happened
Wassil Jim, Chief Operating Officer of Vaxcyte, sold 2,250 shares on May 1, 2026. The filing reports a weighted-average sale price of $56.83 per share for a total reported proceeds of $127,870. This was a sale (not a purchase), which is generally routine insider liquidity rather than a direct bullish signal.

Key Details

• Transaction date: 2026-05-01. Transaction type: Sale (code S), described as open market or private sale.
• Price: Weighted-average $56.83; price range reported in footnote: $56.425 to $57.26.
• Total proceeds reported: $127,870.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes: (1) Sale effected under a Rule 10b5-1 trading plan adopted December 9, 2025. (2) Price is a weighted average; the filer will provide on request the number of shares sold at each separate price.
• Filing timeliness: Period of report and filing date are both 2026-05-01 — reported on time based on the provided data.

Context
Sales made under a pre-established 10b5-1 plan are typically scheduled in advance and can reflect routine diversification or liquidity needs rather than a change in company outlook. No option exercises, gifts, or 10% ownership issues are noted in this filing.